Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

Delayed Quote. Delayed  - 04/28 05:35:06 pm
71.56 EUR   -1.38%
04/28 UCB : ex-dividend day for annual dividend
04/27 UCB : General Meeting of Shareholders
04/26 UCB : receives positive CHMP opinion for CIMZIA® (certolizumab pegol..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

UCB : UCB’s Executive Committee with two new members

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/25/2011 | 07:15am CEST

• Greg Duncan, Executive Vice President, President of North American Operations

• Jean-Christophe Tellier, MD, Executive Vice President, President of European Operations

Vers la version en français

Naar de nederlandstalige versie

BRUSSELS, 25 May 07:00 (CET) - regulated information - With UCB set to enter its growth phase in 2012 and building on major advances in its late-stage pipeline, UCB announced today that two new members will join the company’s Executive Committee as of July 1, 2011.

The two new members are the heads of the US and European commercial operations, respectively Greg Duncan, currently Senior Vice President and President of UCB’s North American Operations, and Jean-Christophe Tellier, joining UCB from Ipsen.

These additions will allow Mark McDade, UCB’s EVP Global Operations and Chief Operating Officer to focus on UCB’s future growth markets outside the US and Europe, while driving UCB’s commercial growth strategy across all geographies. Mark will also continue to lead Business Development and maintains his global leadership of the company’s Marketing, Access and Medical Affairs functions, preparing the launch and commercialization of the next generation of medicines from UCB’s promising late-stage pipeline, such as brivaracetam in epilepsy, epratuzumab in Lupus and Sclerostin antibody in post-menopausal osteoporosis and fracture healing.

Greg Duncan joined UCB in 2007 to lead UCB’s European Operations. He then became President of European and Emerging Market Operations until 2009 when he was appointed President of UCB’s North American operations. Greg has a degree in Economics from the State University of New York, Albany, and a MBA in Marketing and Management from the Emory University in Atlanta. He started his career in 1989, within Pfizer, where he had spent 17 years holding various managerial positions. His last position within Pfizer was as President Latin America.

Jean-Christophe Tellier is joining UCB from Ipsen where he was President & General Manager Ipsen US. His role at Ipsen was to strengthen Ipsen’s specialty care business in North America, in the areas of endocrinology and neurology. Prior to joining Ipsen in May 2009, he was Executive Vice President and Chief Commercial Officer at MacroGenics Inc, a Maryland-based biotechnology company. Jean-Christophe Tellier spent the largest part of his career at Novartis (Ciba) where he held several commercial operations roles in France, Belgium and Switzerland. Jean-Christophe Tellier is a physician specialized in rheumatology (University of Paris V, France).

Detailed biographies of the members of the Executive Committee can be found on UCB’s website.

For further Information:

Antje Witte, Investor Relations, UCB

T +32.2.559.9414,

Michael Tuck-Sherman, Investor Relations, UCB

T +32.2.559.9712, [email protected]@ucb.com

About UCB

UCB, Brussels, Belgium () is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing more than 9000 people in over 40 countries, UCB produced revenue of EUR 3.22 billion in 2010. UCB is listed on Euronext Brussels (symbol: UCB).

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.

www.ucb.com

UCB Media Room

e: [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on UCB
04/28 UCB : ex-dividend day for annual dividend
04/27 UCB : General Meeting of Shareholders
04/26 UCB : receives positive CHMP opinion for CIMZIA® (certolizumab pegol) dose &hell..
04/24 UCB FIRST THREE MONTHS INTERIM REPOR :  UCB with …
04/20 UCB : Findings from UCB S.A. Provides New Data on Epilepsy (Health care cost ass..
04/19UCB SA : quaterly earnings release
04/10 UCB : U.S. Patent and Trademark Office confirms validity of patent …
04/10 UCB : Acquisition of own shares
04/07 UCB : Acquisition of own shares
04/04 UCB : and Q-State Biosciences Form Research Collaboration …
More news
Sector news : Pharmaceuticals - NEC
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Dual-Drug Hepatitis C Treatm..
04/28DJBRISTOL MYERS SQUIBB : China Approves Bristol-Myers Squibb's Dual-Drug Hepatitis..
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27DJASTRAZENECA : Faces Shareholder Uprising Over Changes to Executive Award
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/21 UCB Needs Clinical Success To Drive Upside
02/24 UCB S.A. 2016 Q4 - Results - Earnings Call Slides
02/24 UCB's (UCBJF) CEO Jean-Christophe Tellier on Q4 2016 Results - Earnings Call ..
02/23 UCB S.A. reports FY results
01/10 RHEUMATOID ARTHRITIS : The Big 3 And The Future
Advertisement
Financials (€)
Sales 2017 4 284 M
EBIT 2017 934 M
Net income 2017 597 M
Debt 2017 551 M
Yield 2017 1,68%
P/E ratio 2017 21,46
P/E ratio 2018 17,71
EV / Sales 2017 3,38x
EV / Sales 2018 3,06x
Capitalization 13 919 M
More Financials
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 75,6 €
Spread / Average Target 5,6%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Ismail Kola Chief Scientific Officer, EVP & Head-New Medicines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB17.48%15 162
JOHNSON & JOHNSON7.17%334 714
ROCHE HOLDING LTD.11.91%225 722
NOVARTIS AG3.31%202 360
PFIZER INC.4.43%201 998
MERCK & CO., INC.5.88%170 880
More Results